Eye Care Insider

In this special episode, I sit down with this week's co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.

• Intro :14
• In this episode :21
• About Yasmin P. Mali, MD :35
• Mali's first prediction: The human spirit and innovation will triumph over the headline-dominating COVID-19 1:16
• Yasmin Mali's thoughts on the first predictions 2:58
• Mali's second prediction: The competition battle lines will be drawn for ocular therapeutics in the most common eye disease markets 4:04
• Thoughts on the potential products in 2021 6:25
• Mali's third prediction: Increased use of artificial intelligence in clinical ophthalmology 8:18
• Any advances in artificial intelligence for pediatric ophthalmology? 10:15
• Mali's fourth prediction: Telemedicine platforms will still play a role in ophthalmology 11:24
• Thoughts on telemedicine in the pediatric ophthalmology community 13:44
• Mali's fifth prediction: Virtual ophthalmology conference options will remain present for the majority of 2021 15:17
• Mali's thoughts on the virtual meetings attended in 2020 17:10
• Mali's bonus announcement 18:34
• Yasmin Mali's final words 18:48

Yasmin P. Mali, MD, is a board-certified ophthalmologist and fellowship trained pediatric ophthalmologist. Mali is currently faculty at Lake Erie College of Osteopathic Medicine in Bradenton, Florida.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Yasmin Mali, MD, reports no relevant financial disclosures.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

In this episode, I sit down with wealth management advisor Jose Segura to discuss financial planning for medical professionals. Segura will also discuss some of the better investment strategies for eye care professionals.

• Intro :14
• In this episode :21
• About Segura :30
• The interview 1:30
• Who is Jose Segura? 1:45
• Why the focus on medical professionals and physicians? 3:45
• Where should an eye care professional start regarding financial planning? 6:15
• As a financial professional, what strategies do you use to help them start getting organized? 8:45
• What's the best investment? What do you tell an eye care professional about the different strategies about investing? 11:35
• Is it best to have a team of investors or to have a professional to help navigate changing environments? 15:18
• How do you, from a financial standpoint, help to weather those economic headwinds? What's the best strategy for eye care professionals? 16:40
• What do you think is the most important financial pearl in regards to financial planning and their financial future? 20:35
• Segura's final words 21:55

Jose Segura is a wealth management advisor and business exit planner for Wealth Advisory Group, LLC and a financial advisor with Park Avenue Securities, LLC.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at [email protected], or call 518-221-4832.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I sit down with Kester Nahen, PhD, as we discuss the use of artificial intelligence and telemedicine among retina specialists. Nahen will also discuss Notal Vision's ForseeHome device for monitoring and the company's Home OCT artificial intelligence-enable platform for monitoring AMD.

• Intro :14
• In this episode :21
• About Dr. Nahen 1:24
• The interview 1:42
• The background of Kester Nahen 2:00
• Nahen's thoughts on the current state of telemedicine and artificial intelligence 5:10
• Will artificial intelligence replace the clinical aspect of what we do? 7:42
• About Notal Vision's ForseeHome Device 9:30
• The AMD criteria required for use of ForseeHome 11:54
• As a result of COVID-19, has there been an increased interest in using ForseeHome? 13:15
• What is the best way for ophthalmologists and eyecare providers to get more information about the ForseeHome program? 14:40
• More details on Notal Vision's Home OCT and will it really change and revolutionize the way retina specialists monitor patients? 16:00
• What's the status of the FDA approval process for the Home OCT? 21:10
• What does Nahen think is the most important topic facing the ophthalmology industry today and what will be in the future? 23:05
• Nahen's final thoughts 25:30

Kester Nahen, PhD, is the chief executive officer at Notal Vision.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nahen is the CEO of Notal Vision.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

In part 1 of this two-part series, I sit down with George B. Bartley, MD, who details the history of the American Board of Ophthalmology, plus everything you ever wanted to know about board certification and maintaining your certificate.

• Intro :14
• In this episode :24
• About Dr. Bartley :49
• The interview 1:06
• Who is Dr. Bartley? 1:09
• History of the ABO and Dr. Bartley's journey with them 3:51
• What are the benefits of having board certification? 7:50
• What are the initial steps to becoming board certified? 11:46
• What happens next with the postponement? 17:21
• Once you're board certified, how does maintenance of certification (MOC) work? 23:25
• How does one pass the quarterly questions? 33:03
• How many years do people need to pass to maintain certification? 35:08
• CME vs. self-assessment CME 36:20
• Are there any potential changes to the certification process? 37:53
• What's the most important issue facing the ABO, now or in the future? 41:05
• Thank you for your service to the ABO, Dr. Bartley 42:20

George B. Bartley, MD, is chief executive officer, American Board of Ophthalmology; chief executive officer, Mayo Clinic in Florida; and The Louis and Evelyn Krueger Professor of Ophthalmology, Mayo Clinic.

Disclosures: Bartley reports the American Board of Ophthalmology reimburses Mayo Clinic for a portion of his salary and benefits. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Information about certification and maintaining certification can be found on the American Board of Ophthalmology's website: https://abop.org. For news, updates, and announcements, visit the board's blog at https://diplomatedigest.com. To receive personalized assistance maintaining ABO certification, contact Amy Savastano, diplomate success specialist, at 610-664-1175 or [email protected].

In this interview with Joseph Nezgoda, MD, MBA, we discuss young ophthalmologists – or YOs – and the most important challenges this group faces. Nezgoda also provides his insight and advice for YOs embarking on their career.

• Intro :13
• In this episode :15
• About Dr. Nezgoda :23
• The interview :54
• Who is Dr. Nezgoda? 1:29
• "Ah-ha" moments 4:13
• What is a young ophthalmologist, or YO? 8:07
• What is the most important topic or challenge currently facing YOs? 9:57
• What's the ideal path – academic, private practice, or a hybrid? 11:41
• How did you get involved in advocacy? 16:24
• What do you think will be the biggest challenge for YOs in the future? 22:42
• Any last advice for YOs starting their career? 26:53
• Thanks for listening! 29:35

Joseph Nezgoda, MD, MBA, is an ophthalmologist and retina specialist in private practice at Retina Macula Institute in West Palm Beach, Fla. He is also vice president of education at Florida Society of Ophthalmology; editor of ONE Network Retina, American Academy of Ophthalmology; and delegate to the AMA, American Society of Retina Specialists.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nezgoda reports no relevant financial disclosures.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Dr. Nezgoda can be reached via www.retinamacula.org

In this episode, John S. Pollack, MD, discusses how he got started with the American Society of Retina Specialists, gives the scoop on the PAT survey and provides career advice for young retina specialists.

• Intro :15
• In this episode :18
• About Dr. Pollack :24
• The interview :45
• Who is Dr. Pollack? 1:10
• What's your favorite part about the field of retina? 2:37
• How did you get involved with the ASRS? 3:58
• Who write the questions for the PAT survey? 5:54
• How should community retina specialists utilize and view the PAT survey? 7:04
• Are you currently taking responses? 7:50
• What are the top issues ASRS will be dealing with this year? 8:12
• Indications for surgery for epiretinal membranes: visual acuity or visual function? 8:50
• What will have the biggest impact on retina for years to come? 15:28
• Career advice for young retina specialists; academic vs. private practice? 18:49
• Do you factor health care policy/reform into this decision? In 5 years, will health care be the same? 21:32
• The Winning Pitch Challenge 22:51
• How an idea in clinic turned into a product 26:45
• Thanks for listening! 28:00

John S. Pollack, MD, is past president of the American Society of Retina Specialists; partner at Illinois Retina Associates, Rush University Medical Center in Chicago.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Pollack reports grant/research support from Aldeyra; consulting for Allergan, Dutch Ophthalmic Research Company, Graybug, Regeneron, REGENXBIO and Santen; founder and stock at Covalent Medical; grant support and consulting from Genentech; BOD, stock and consultant for Notal Vision; and founder and stock at Vestrum Health.

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN